Pulse Brain · Growing Health Evidence Index
Peer-reviewed

<scp>P</scp>athogenic and targetable genetic alterations in 70 urachal adenocarcinomas

Henning Reis, Kristan E. van der Vos, Christian Niedworok, Thomas Herold, Orsolya Módos, Attila Szendrői, Thomas Hager, Marc Ingenwerth, Daniël J. Vis, Mark A. Behrendt, Jeroen de Jong, Michiel S. van der Heijden, B. Peyronnet, Romain Mathiéu, Marcel Wiesweg, Jason Ablat, Krzysztof Okoń, Yuri Tolkach, Dávid Keresztes, Nikolett Nagy, Felix Bremmer, Nadine T. Gaisa, Piotr Chłosta, Joerg Kriegsmann, Ilona Kovalszky, József Tı́már, Glen Kristiansen, Heinz‐Joachim Radzun, Ruth Knüchel, Martin Schüler, Peter C. Black, H. Rübben, Boris Hadaschik, Kurt Werner Schmid, Bas W.G. van Rhijn, Péter Nyírády, Tibor Szarvas

International Journal of Cancer · 2018

Read source ↗ All evidence

Summary

Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly be conducted. Targeted therapeutic treatment approaches and potentially immunotherapy based on a biological rationale may provide an alternative strategy. We therefore subjected 70 urachal adenocarcinomas to targeted next-generation sequencing, conducted in situ and immunohistochemical analyses (including PD-L1 and DNA mismatch repair proteins [MMR]) and evaluated the microsatellite instability (MSI) status. The analytical findings were correlated with clinicopathological and outcome data and Kaplan-Meier and univariable/multivariable Cox regression analyses were perform

Source type
Peer-reviewed study
DOI
10.1002/ijc.31547
Catalogue ID
BFmoef2rp2-pgfda9
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.